Insider Transactions in Q2 2023 at Entrada Therapeutics, Inc. (TRDA)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 29
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,790
+19.3%
|
$17,580
$2.1 P/Share
|
|
Jun 22
2023
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
7,097
-14.32%
|
$113,552
$16.02 P/Share
|
|
Jun 21
2023
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
17,500
-21.53%
|
$262,500
$15.01 P/Share
|
|
Jun 21
2023
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+27.8%
|
$35,000
$2.1 P/Share
|
|
Jun 20
2023
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
8,885
-15.2%
|
$124,390
$14.94 P/Share
|
|
Apr 27
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
2,000
-0.98%
|
$26,000
$13.71 P/Share
|
|
Apr 17
2023
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
3,961
-2.26%
|
$71,298
$18.0 P/Share
|
|
Apr 17
2023
|
Dipal Doshi CEO |
SELL
Open market or private sale
|
Direct |
2,092
-1.01%
|
$37,656
$18.01 P/Share
|